Navigation Links
Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
Date:10/11/2011

ANAHEIM, Calif., Oct. 11, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2011 financial results on Tuesday, October 25, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and slide presentation via webcast on Tuesday, October 25, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the third quarter, as well as current corporate developments.  

Conference call details:Date:Tuesday, October 25, 2Time:4:30 p.m. ETDial-in (U.S.):877-941-1465Dial-in (International):480-629-9643Web cast:www.questcor.comTo access an audio replay of the call:

Replay (U.S.):800-406-7325Replay (International):303-590-303Replay Passcode:4480054About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
3. Questcor Provides Updated New Paid Prescription Trends
4. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
5. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
6. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
7. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
8. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
9. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
10. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
11. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... global biosurgery market is expected to grow at a ... to 2021. The market is poised to reach USD ... 2016. The market is primarily driven by rising number ... spinal problems, increasing clearance of biosurgery products by regulatory ... In this report, the biosurgery market is ...
(Date:12/8/2016)... Pharmacy, Inc. (NYSE: DPLO) has been recognized by the Detroit ... Standard. To learn more about Diplomat,s career opportunities, visit ... ... ... LLC, a research firm specializing in organizational health and workplace improvement. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... version gives development continuity to its innovative Unified Instance Manager architecture, meeting ... In addition, this new version optimizes the unattended auto-dialing system without agents, ...
Breaking Medicine News(10 mins):